Newsroom

April 13, 2021-Highly accomplished attorney joins Sera to develop its legal and intellectual property functions.

March 31, 2021- Accomplished technology leader joins Sera to build and deploy its information strategy.

February 3, 2021- Receipt of dedicated CPT® code marks important commercialization milestone to pursue reimbursement for the PreTRM® Test.

January 05, 2021- Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care.

September 9, 2020- Sera will be presenting at the upcoming Baird 2020 Global Health Care Conference. A virtual conference, Sera’s presentation will take place on Thursday, September 10 at 10:50 a.m. ET.

June 24, 2020 – Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. – Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company.

May 20, 2020 – Sera, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.

April 2, 2020 – Sera announced the appointment of Jay M. Moyes as Chief Financial Officer.

Feb 24, 2020 — Sera will be presenting at the upcoming Cowen 2020 Health Care Conference at the Boston Marriott Copley Place in Boston on Tuesday, March 3rd, at 11:30 a.m. ET.

Jan 28, 2020 — Sera announced two podium presentations describing the performance of the company’s technologies for predicting the individual risk of prematurity for women when prospectively tested in mid pregnancy.